

Stephanie Agu

Associate

Washington, D.C.

Biography

Stephanie Agu designs legal and policy solutions for life science and health care companies in a stringent regulatory environment.

She advises clients on state and federal regulatory issues that may arise throughout a product's life, from patent concerns to drug promotion and advertising questions. Stephanie is dedicated to providing sophisticated work to guide clients through a complex and intricate legal landscape.

Stephanie's practice focuses on issues concerning product development, lifecycle management, FDA regulatory compliance and enforcement, and clinical trial development activities. She also counsels companies on how to navigate the emerging cannabis market. Stephanie routinely advises pharmaceutical companies on advertising and promotional issues concerning pre-launch and post-marketing communications, has assisted clients with internal investigations related to promotional activities, and has served on promotional review committees.

Stephanie began her career at Hogan Lovells as a summer associate in 2018. She also maintains an active pro bono practice. While attending the University of Texas School of Law, she successfully defended a tenant on the brink of eviction. She also participated in expungement clinics and advised artists and small businesses on how to meet their goals. Before law school, she worked as a consultant to Fortune 500 companies.



Phone

+1 202 637 2095

Fax

+1 202 637 5910

Email

stephanie.agu@hoganlovells.com

Languages

English

Practices

Pharmaceuticals and Biotechnology
Regulatory

Industries

Life Sciences and Health Care

Education and admissions

Education

J.D., The University of Texas School
of Law, 2019

B.A., Rice University, 2014

Latest thinking and events

- Hogan Lovells Podcasts
 - Podcast: Talking the cure
- News
 - FDA issues ambitious new draft guidance to promote clinical trial diversity
- News
 - DEA proposes revised rules for identifying and reporting suspicious orders of controlled substances
- News
 - Trump administration reversal would take away FDA's authority to approve biosimilars

Bar admissions and qualifications

District of Columbia
